

AMENDMENTS TO THE CLAIMS

1. (Currently Canceled)

2. (Canceled)

3. (Currently Canceled)

4. (Currently Canceled)

5. (Canceled)

6. (Currently Twice Amended) A composition comprising a polypeptide comprising a single interleukin-8 (IL-8) fragment and a pharmaceutically acceptable carrier, wherein said IL-8 fragment stimulates the differentiation of fibroblasts to myofibroblasts, and wherein said fragment comprises an ELR motif ~~The polypeptide of claim 1, wherein the IL-8 fragment comprises and an amino acid sequence that is at least 70% identical to an N-terminal amino acid sequence of IL-8, and is no greater than about 15 amino acids in length, wherein the N-terminal amino acid sequence comprises a subsequence of residues 1-36 of SEQ ID NO.: 5 or residues 1-38 of SEQ ID NO.: 4.~~

7. (Currently Twice Amended) A composition comprising a polypeptide comprising a single interleukin-8 (IL-8) fragment and a pharmaceutically acceptable carrier, wherein said IL-8 fragment stimulates the differentiation of fibroblasts to myofibroblasts, and wherein said fragment comprises an ELR motif and ~~The polypeptide of claim 1, wherein the IL-8 fragment comprises an amino acid sequence that is at least 90% identical to an N-terminal amino acid sequence of IL-8, and is no greater than about 15 amino acids in length, wherein the N-terminal amino acid sequence comprises a subsequence of residues 1-36 of SEQ ID NO.: 5 or residues 1-38 of SEQ ID NO.: 4.~~

8. (Currently Twice Amended) A composition comprising a polypeptide comprising a single interleukin-8 (IL-8) fragment and a pharmaceutically acceptable carrier, The polypeptide of claim 7, wherein the IL-8 fragment comprises an amino acid sequence selected from

the group consisting of SEQ ID NO:8 and SEQ ID NO:9, and is no greater than about 15 amino acids in length.

9-18. (Canceled)

19. (Currently Canceled)

20-86. (Canceled)

87. (Currently Amended) The polypeptide of claim 16, 7, or 8, wherein the polypeptide is a cyclic polypeptide.

88. (Currently Amended) A polypeptide comprising a single interleukin-8 (IL-8) fragment, wherein said IL-8 fragment The polypeptide of claim 1, wherein the IL-8 fragment comprises consists of the amino acid sequence SAKELR (SEQ ID NO.: 8).

89. (Currently Amended) A polypeptide comprising a single interleukin-8 (IL-8) fragment, wherein said IL-8 fragment stimulates the differentiation of fibroblasts to myofibroblasts, comprises an ELR motif, and is no greater than about 15 amino acids in length, and The polypeptide of claim 1, wherein the IL-8 fragment comprises an amino acid sequence variant of SAKELR (SEQ ID NO.: 8), wherein the amino acid sequence variant has a conservative amino acid substitution of one amino acid of the SAKELR (SEQ ID NO.: 8).

90. (Currently Amended) A polypeptide comprising a single interleukin-8 (IL-8) fragment, wherein said IL-8 fragment The polypeptide of claim 1, wherein the IL-8 fragment comprises consists of the amino acid sequence AVLPRSAKELR (SEQ ID NO.: 9).

91. (Currently Amended) A polypeptide comprising a single interleukin-8 (IL-8) fragment, wherein said IL-8 fragment stimulates the differentiation of fibroblasts to myofibroblasts, comprises an ELR motif, and is no greater than about 15 amino acids in length, and The polypeptide of claim 1, wherein the IL-8 fragment comprises an amino acid sequence variant of AVLPRSAKELR (SEQ ID NO.: 9), wherein the amino acid sequence variant has a conservative amino acid substitution of one amino acid of the AVLPRSAKELR (SEQ ID NO.: 9).

92. (Previously Added) A composition comprising the polypeptide of claim 88, 89, 90 or 91 and a pharmaceutically acceptable carrier.

93. (Previously Added) The polypeptide of claim 88, 89, 90 or 91, wherein the polypeptide is a cyclic polypeptide.

94. (New) The composition of claim 6, wherein the N-terminal amino acid sequence comprises the subsequence of residues 1-36 of SEQ ID NO.: 5.

95. (New) The composition of claim 6, wherein the N-terminal amino acid sequence comprises the subsequence of residues 1-38 of SEQ ID NO.: 4.

96. (New) The composition of claim 6, wherein said fragment is no greater than about 8 amino acids in length.

97. (New) The composition of claim 7, wherein the N-terminal amino acid sequence comprises the subsequence of residues 1-36 of SEQ ID NO.: 5.

98. (New) The composition of claim 7, wherein the N-terminal amino acid sequence comprises the subsequence of residues 1-38 of SEQ ID NO.: 4.

99. (New) The composition of claim 7, wherein said fragment is no greater than about 8 amino acids in length.

100. (New) The composition of claim 8, wherein the IL-8 fragment comprises SEQ ID NO: 8.

101. (New) The composition of claim 8, wherein the IL-8 fragment comprises SEQ ID NO: 9.